Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 107-114

  Freeling, Jennifer P ^a   Koehn, Josefin ^a   Shu, Cuiling ^a   Sun, Jianguo ^a,b   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; RITONAVIR; SOLID LIPID NANOPARTICLE; TENOFOVIR; ADENINE; DRUG CARRIER; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LIPID; NANOPARTICLE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHILICITY; INFLAMMATION; INGUINAL LYMPH NODE; MACACA; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SUSPENSION; YOUNG ADULT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DRUG COMBINATION; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPH NODE; VIROLOGY; VIRUS LATENCY; VIRUS LOAD;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG CARRIERS; DRUG COMBINATIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; INDINAVIR; LIPIDS; LOPINAVIR; LYMPH NODES; MACACA; NANOPARTICLES; ORGANOPHOSPHONATES; RITONAVIR; TENOFOVIR; VIRAL LOAD; VIRUS LATENCY;

EID: 84937138894     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0210     Document Type: Article

References (31)

1. Chun TW, Davey RTJ, Engel D, et al.: Re-emergence of HIV after stopping therapy. Nature 1999;401(6756):874-875
2. Wong JK, Gunthard HF, Havlir DV, et al.: Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997;94(23):12574-12579
3. Horiike M, Iwami S, Kodama M, et al.: Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 2011;423(2):107-118
4. Lafeuillade A, Chollet L, Hittinger G, et al.: Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of 200 copies/mL. J Infect Dis 1998 177 (1) 235-238
5. Siliciano JD, Kajdas J, Finzi D, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 + T cells. Nat Med 2003;9(6):727-728
6. Fletcher CV, Staskus K, Wietgrefe SW, et al.: Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014;111(6):2307-2312
7. Kinman L, Brodie SJ, Tsai CC, et al.: Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: A proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr 2003;34(4):387-397
8. Solas C, Lafeuillade A, Halfon P, et al.: Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47(1):238-243
9. Cavert W, Notermans DW, Staskus K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276(5314):960-964
10. Pantaleo G, Graziosi C, Demarest JF, et al.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362(6418): 355-358
11. Kinman L, Bui T, Larsen K, et al.: Optimization of lipidindinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr 2006;42(2):155-161
12. Choi SU, Bui T, and Ho RJ: pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J Pharm Sci 2008;97(2):931-943
13. Notermans DW, Jurriaans S, de Wolf F, et al.: Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. AIDS 1998;12(2): 167-173
14. Martinez E, Arnedo M, Giner V, et al.: Lymphoid tissue viral burden and duration of viral suppression in plasma. AIDS 2001;15(12):1477-1482
15. Palella FJ, Jr., Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-860
16. Koehn J and Ho RJ: Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs lopinavir, ritonavir, and tenofovir in plasma. Antimicrob Agents Chemother 2014;58(5):2675-2680
17. Hsu A, Granneman GR, and Bertz RJ: Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35(4):275-291
18. Storch CH, Theile D, Lindenmaier H, et al.: Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007;73(10):1573-1581
19. Piliero PJ: Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S2-S12
20. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968;97:77-89
21. Alberts B, Johnson A, Lewis J, et al.: Molecular Biology of the Cell, 4 ed. Garland Science, New York, 2002
22. Kuo YC and Chung CY: Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids Surf B Biointerfaces 2011;88(2):682-690
23. Nowacek AS, McMillan J, Miller R, et al.: Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: Implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol 2010;5(4):592-601
24. Shibata A, McMullen E, Pham A, et al.: Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retroviruses 2013; 29(5):746-754
25. Oussoren C, Zuidema J, Crommelin DJ, and Storm G: Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1997;1328(2):261-272
26. Robison LS, Westfall AO, Mugavero MJ, et al.: Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008;24(11):1347-1355
27. Cicconi P, Cozzi-Lepri A, Castagna A, et al.: Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med 2010; 11(2):104-113
28. Bui T, Stevenson J, Hoekman J, et al.: Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging. PLoS One 2010;5(9):e13082
29. Straubinger RM, Duzgunes N, and Papahadjopoulos D: pHsensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett 1985;179(1):148-154
30. Endsley AN and Ho RJ: Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles. J Acquir Immune Defic Syndr 2012;61(4):417-424
31. Gunaseelan S, Gunaseelan K, Deshmukh M, et al.: Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv Drug Deliv Rev 2010;62(4-5): 518-531